Findings

What do systematic reviews say?

2 questions · 3 findings · 1 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 66.7%Low 1 · 33.3%Moderate 0 · 0%High 0 · 0%

Anti‐EGFR antibody plus chemotherapy vs chemotherapy alone

Grade 3 to 4 diarrhoea · treatment of relapsed epithelial ovarian cancer

It is very uncertain whether anti‐EGFR antibody plus chemotherapy changes toxicity: grade 3 or 4 diarrhoea compared with chemotherapy alone (very low certainty).

2 findings from 1 review

Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
RR 2.87 [0.59, 13.89]
4 studies · 652 participants
Very low
Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
RR 6.37 [1.89, 21.45]
3 studies · 432 participants
Low

Anti‐EGFR antibody plus chemotherapy vs chemotherapy alone

Grade ≥ 3 diarrhoea · treatment of relapsed epithelial ovarian cancer

It is very uncertain whether anti‐EGFR antibody plus chemotherapy changes toxicity: grade 3 or 4 diarrhoea ‐ seribantumab compared with chemotherapy alone (very low certainty).

1 finding from 1 review

Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
RR 0.38 [0.07, 2.23]
1 study · 220 participants
Very low